STOPCAP M1, aggregate data network meta-analysis
What is the optimal systemic treatment of men with metastatic, hormone-sensitive prostate cancer? a systematic review and network meta-analyses of aggregate data
Which treatments work best for men with metastatic, hormone-sensitive prostate cancer?
What was this study about?
A network meta-analyses was carried out bringing together results of trials that had compared different recent treatments that had been tested in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer. We looked at how the effective the treatments were and established which were best.
What difference did this study make?
Abiraterone in addition to ADT has the highest probability of being the most effective treatment with docetaxel in addition to ADT, the second best treatment. Either of these treatments should be used in men with metastatic, hormone-sensitive prostate cancer.
Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals Oncology. 2018;29(5):1249-57
Type of study
Who funded the study?
Prostate Cancer UK and Medical Research Council, UK
When did it take place?
This study was fully published in 2018 and brought together the results of six trials that were carried out between 2004 and 2014.
Where did it take place?
This study was done at the MRC Clinical Trials Unit at UCL but brings together the results of trials carried out worldwide.
Who was included?
This study brought together six trials (6204 patients) that studied seven treatment combinations. These were, ADT, celecoxib, zolendronic acid, docetaxel and abiraterone (and combinations of these treatments)